19. ライソゾーム病 Lysosomal storage disease Clinical trials / Disease details

臨床試験数 : 854 / 薬物数 : 716 - (DrugBank : 105) / 標的遺伝子数 : 70 - 標的パスウェイ数 : 191

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03632213 (ClinicalTrials.gov)	November 7, 2018	3/8/2018	Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI	A Randomized Clinical Trial to Evaluate the Effects of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI	Mucopolysaccharidosis IV A;Mucopolysaccharidosis VI;Mucopolysaccharidoses;MPS IV A;MPS VI;MPS - Mucopolysaccharidosis;Morquio A Syndrome;Morquio Syndrome A;Morquio Syndrome	Drug: Losartan;Drug: Placebo	Hospital de Clinicas de Porto Alegre	The Isaac Foundation	Recruiting	10 Years	40 Years	All	30	Phase 2	Brazil
2	NCT00446862 (ClinicalTrials.gov)	March 2007	11/3/2007	The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study	Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET Study	Fabry Disease;Proteinuria	Drug: enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers	University of Alabama at Birmingham	NULL	Completed	19 Years	85 Years	Both	36	N/A	United States;Slovenia;Germany